Overview

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Status:
Recruiting
Trial end date:
2023-12-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb